Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INT2104 |
| Synonyms | |
| Therapy Description |
INT2104 comprises a lentiviral vector that transduces CD7-expressing T-cells with a chimeric antigen receptor (CAR) targeting CD20, potentially resulting in depletion of B-cells and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2023;11). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INT2104 | INT-2104|INT 2104 | CD20 Antibody 26 | INT2104 comprises a lentiviral vector that transduces CD7-expressing T-cells with a chimeric antigen receptor (CAR) targeting CD20, potentially resulting in depletion of B-cells and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2023;11). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06539338 | Phase I | INT2104 | Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment (INVISE) | Recruiting | AUS | 0 |